Results 31 to 40 of about 743,371 (240)

The role of BET attenuation in melanoma [PDF]

, 2022
Bromodomain and extra-terminal (BETs) proteins function as epigenetic readers by docking onto acetylated lysine residues (Kac) on histone tails via tandem bromodomains (BRDs), and recruiting protein binding partners via an extra-terminal recruitment ...
Henderson, Elizabeth K
core   +1 more source

Regulation of inflammatory genes in decidual cells: Involvement of the bromodomain and extra-terminal family proteins.

PLoS ONE, 2023
The decidua undergoes proinflammatory activation in late pregnancy, promoting labor. Bromodomain and Extra-Terminal (BET) family proteins interact with acetylated histones and may control gene expression in inflammation.
Sandeep Ajgaonkar, Jonathan J Hirst, Mary Norris, Tamas Zakar   +3 more
doaj   +1 more source

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers [PDF]

Journal of Immunotherapy and Precision Oncology, 2020
The bromodomain and extraterminal (BET) domain protein family is involved in the process of transcription of genetic information. The BET protein family includes BRD2, BRD3, BRD4, and bromodomain testis-specific protein.
Martin V. Nguyen, Lydia Loof, Gerald S. Falchook   +2 more
doaj   +1 more source

Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death

Frontiers in Oncology, 2022
BackgroundColorectal cancer (CRC) frequently has a dysregulated epigenome causing aberrant up-regulation of oncogenes such as c-MYC. Bromodomain and extra-terminal domain (BET) proteins and histone acetyltransferases (HAT) are epigenetic regulatory ...
Chaoyuan Kuang, Chaoyuan Kuang, Jingshan Tong, Jingshan Tong, Kaylee Ermine, Kaylee Ermine, Manbo Cai, Manbo Cai, Fujun Dai, Fujun Dai, Suisui Hao, Suisui Hao, Francis Giles, Yi Huang, Yi Huang, Jian Yu, Jian Yu, Lin Zhang, Lin Zhang   +18 more
doaj   +1 more source

BET Bromodomain Inhibitors Suppress Inflammatory Activation of Gingival Fibroblasts and Epithelial Cells From Periodontitis Patients

Frontiers in Immunology, 2019
BET bromodomain proteins are important epigenetic regulators of gene expression that bind acetylated histone tails and regulate the formation of acetylation-dependent chromatin complexes.
Anna Maksylewicz, Agnieszka Bysiek, Katarzyna B. Lagosz, Justyna M. Macina, Malgorzata Kantorowicz, Grzegorz Bereta, Maja Sochalska, Katarzyna Gawron, Maria Chomyszyn-Gajewska, Jan Potempa, Jan Potempa, Aleksander M. Grabiec   +11 more
doaj   +1 more source

BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4

Scientific Reports, 2021
Hepatocellular carcinoma (HCC) is one of the most prevalent and poorly responsive cancers worldwide. Bromodomain and extraterminal (BET) inhibitors, such as JQ1 and OTX-015, inhibit BET protein binding to acetylated residues in histones.
Hae In Choi, Ga Yeong An, Mina Baek, Eunyoung Yoo, Jin Choul Chai, Young Seek Lee, Kyoung Hwa Jung, Young Gyu Chai   +7 more
doaj   +1 more source

BRD3 Regulates the Inflammatory and Stress Response in Rheumatoid Arthritis Synovial Fibroblasts

Biomedicines, 2023
Background: Individual functions of members of the bromodomain (BRD) and extra-terminal (BET) protein family underlying the anti-inflammatory effects of BET inhibitors in rheumatoid arthritis (RA) are incompletely understood.
Tanja Seifritz, Matthias Brunner, Eva Camarillo Retamosa, Malgorzata Maciukiewicz, Monika Krošel, Larissa Moser, Thomas Züllig, Matija Tomšič, Oliver Distler, Caroline Ospelt, Kerstin Klein   +10 more
doaj   +1 more source

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma

Nature Communications, 2019
BET-bromodomain inhibitors could be used to treat medulloblastoma tumors with Myc amplifications. Here, the authors show that both the response and resistance to BET inhibitors in mice is mediated by bHLH/homeobox transcription factors.
Pratiti Bandopadhayay, Federica Piccioni, Ryan O’Rourke, Patricia Ho, Elizabeth M. Gonzalez, Graham Buchan, Kenin Qian, Gabrielle Gionet, Emily Girard, Margo Coxon, Matthew G. Rees, Lisa Brenan, Frank Dubois, Ofer Shapira, Noah F. Greenwald, Melanie Pages, Amanda Balboni Iniguez, Brenton R. Paolella, Alice Meng, Claire Sinai, Giovanni Roti, Neekesh V. Dharia, Amanda Creech, Benjamin Tanenbaum, Prasidda Khadka, Adam Tracy, Hong L. Tiv, Andrew L. Hong, Shannon Coy, Rumana Rashid, Jia-Ren Lin, Glenn S. Cowley, Fred C. Lam, Amy Goodale, Yenarae Lee, Kathleen Schoolcraft, Francisca Vazquez, William C. Hahn, Aviad Tsherniak, James E. Bradner, Michael B. Yaffe, Till Milde, Stefan M. Pfister, Jun Qi, Monica Schenone, Steven A. Carr, Keith L. Ligon, Mark W. Kieran, Sandro Santagata, James M. Olson, Prafulla C. Gokhale, Jacob D. Jaffe, David E. Root, Kimberly Stegmaier, Cory M. Johannessen, Rameen Beroukhim   +55 more
doaj   +1 more source

BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell. [PDF]

PLoS ONE, 2016
Displacement of Bromodomain and Extra-Terminal (BET) proteins from chromatin has promise for cancer and inflammatory disease treatments, but roles of BET proteins in metabolic disease remain unexplored.
Jude T Deeney, Anna C Belkina, Orian S Shirihai, Barbara E Corkey, Gerald V Denis   +4 more
doaj   +1 more source

BET Inhibition Induces HEXIM1- and RAD51-Dependent Conflicts between Transcription and Replication

Cell Reports, 2018
Summary: BET bromodomain proteins are required for oncogenic transcription activities, and BET inhibitors have been rapidly advanced into clinical trials.
Akhil Bowry, Ann Liza Piberger, Patricia Rojas, Marco Saponaro, Eva Petermann   +4 more
doaj   +1 more source